

Prevention of herpes zoster: recommendations of the A Immunization Practices (ACIP)

MMWR Recommendations and Reports
57, 1-30; quiz CE2-4

Citation Report

#	ARTICLE	IF	CITATIONS
1	Herpes Zoster and Postherpetic Neuralgia in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2007, 23, 615-632.	1.0	52
2	Tumor necrosis factor inhibitors and infection complications. <i>Current Rheumatology Reports</i> , 2008, 10, 383-389.	2.1	33
3	Herpes zoster in the T1 dermatome presenting with Horner’s syndrome, radicular weakness, and postherpetic neuralgia. <i>International Medical Case Reports Journal</i> , 2008, 1, 1.	0.3	2
4	Herpes Zoster Associated Hospital Admissions in Italy: Review of the Hospital Discharge Forms. <i>International Journal of Environmental Research and Public Health</i> , 2009, 6, 2344-2353.	1.2	16
5	Herpes Zoster and Postherpetic Neuralgia: Past, Present and Future. <i>Pain Research and Management</i> , 2009, 14, 275-282.	0.7	43
6	The risk of herpes zoster: another cost of anti-TNF therapy?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 361-363.	3.5	11
7	Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1364-1371.	2.9	192
8	Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older. <i>Vaccine Journal</i> , 2009, 16, 646-652.	3.2	30
9	Varicella Zoster Virus (VZV) in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2009, 9, S108-S115.	2.6	82
10	Optimal timing of routine vaccination in HIV-infected persons. <i>Current HIV/AIDS Reports</i> , 2009, 6, 93-99.	1.1	7
12	Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?. <i>Arthritis Research and Therapy</i> , 2009, 11, 253.	1.6	35
13	Overview of vaccination policies for the elderly in Western European countries. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 210-215.	1.4	9
14	Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster. <i>Pharmacoeconomics</i> , 2009, 27, 1005-1016.	1.7	40
15	Herpes Zoster and Exposure to the Varicella Zoster Virus in an Era of Varicella Vaccination. <i>American Journal of Public Health</i> , 2010, 100, 1116-1122.	1.5	38
16	Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy. <i>BMC Public Health</i> , 2010, 10, 333.	1.2	8
17	Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. <i>BMC Health Services Research</i> , 2010, 10, 237.	0.9	41
18	The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. <i>BMC Medicine</i> , 2010, 8, 37.	2.3	282
19	Varicella Vaccination in Children With Inflammatory Bowel Disease Receiving Immunosuppressive Therapy. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 50, 562-565.	0.9	65

#	ARTICLE	IF	CITATIONS
20	Insulin Degrading Enzyme Induces a Conformational Change in Varicella-Zoster Virus gE, and Enhances Virus Infectivity and Stability. PLoS ONE, 2010, 5, e11327.	1.1	24
21	Herpes Simplex Virus 2 ICP0 ^Δ Mutant Viruses Are Avirulent and Immunogenic: Implications for a Genital Herpes Vaccine. PLoS ONE, 2010, 5, e12251.	1.1	38
22	Impact of Varicella Vaccine on Varicella-Zoster Virus Dynamics. Clinical Microbiology Reviews, 2010, 23, 202-217.	5.7	107
23	Herpes zoster vaccine for the elderly: boosting immunity. Aging Health, 2010, 6, 169-176.	0.3	9
24	Tumor necrosis factor blockade and the risk of viral infection. Nature Reviews Rheumatology, 2010, 6, 165-174.	3.5	148
25	Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology, 2010, 49, 1815-1827.	0.9	176
26	Prevention strategies for herpes zoster and post-herpetic neuralgia. Journal of Clinical Virology, 2010, 48, S14-S19.	1.6	28
27	Zoster Vaccine (Zostavax [®]). Drugs and Aging, 2010, 27, 159-176.	1.3	71
28	Herpes Zoster and Postherpetic Neuralgia Surveillance Using Structured Electronic Data. Mayo Clinic Proceedings, 2011, 86, 1146-1153.	1.4	98
29	Post-Shingles Neuralgia by Any Definition Is Painful, but Is It PHN?. Mayo Clinic Proceedings, 2011, 86, 1141-1142.	1.4	18
30	Herpes Zoster Recurrences More Frequent Than Previously Reported. Mayo Clinic Proceedings, 2011, 86, 88-93.	1.4	184
31	The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Research and Therapy, 2011, 13, R174.	1.6	92
32	Frequency of Herpes Zoster Recurrence. Mayo Clinic Proceedings, 2011, 86, 586.	1.4	11
33	Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain, Behavior, and Immunity, 2011, 25, 759-766.	2.0	74
34	Seroepidemiologic Survey of Varicella-Zoster Virus in Korean Adults Using Glycoprotein Enzyme Immuno Assay and Fluorescent Antibody to Membrane Antigen Test. Annals of Dermatology, 2011, 23, 39.	0.3	8
35	Communication gaps between physicians and patients with postherpetic neuralgia: results from a national study on practice patterns. Journal of Pain Research, 2011, 4, 407.	0.8	4
36	Taking stock of infections and antibiotic resistance in the elderly and long-term care facilities: A survey of existing and upcoming challenges. European Journal of Microbiology and Immunology, 2011, 1, 190-197.	1.5	20
37	Review: The neurobiology of varicella zoster virus infection. Neuropathology and Applied Neurobiology, 2011, 37, 441-463.	1.8	104

#	ARTICLE	IF	CITATIONS
38	Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. <i>Journal of Internal Medicine</i> , 2011, 269, 496-506.	2.7	33
39	Pharmacokinetics and Safety of FV-100, a Novel Oral Anti-Herpes Zoster Nucleoside Analogue, Administered in Single and Multiple Doses to Healthy Young Adult and Elderly Adult Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2847-2854.	1.4	37
40	Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. <i>Infection</i> , 2011, 39, 537-544.	2.3	132
41	Herpes Zoster Ophthalmicus. <i>Current Treatment Options in Neurology</i> , 2011, 13, 79-91.	0.7	47
42	Varicella Zoster Virus DNA at Inoculation Sites and in Saliva After Zostavax Immunization. <i>Journal of Infectious Diseases</i> , 2011, 203, 1542-1545.	1.9	23
43	Safety and tolerability of zoster vaccine in adults ≥60 years old. <i>Hum Vaccin</i> , 2011, 7, 1130-1136.	2.4	40
44	Comparing Shingles Incidence and Complication Rates From Medical Record Review and Administrative Database Estimates: How Close Are They?. <i>American Journal of Epidemiology</i> , 2011, 174, 1054-1061.	1.6	79
45	Prevention of infections in patients with autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2011, 7, 198-200.	3.5	13
46	Predictors of Shingles Reports at Diagnosis of Common Variable Immunodeficiency and Selective Immunoglobulin G Subclass Deficiency in 212 Alabama Adults. <i>Gastroenterology Insights</i> , 2012, 4, e34.	0.7	3
47	Health Supervision in the Management of Children and Adolescents With IBD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 93-108.	0.9	100
48	Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 43-9.	3.8	246
49	Vaccination in solid-organ transplantation candidates: time for a benefit/risk assessment. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 193-194.	1.4	0
50	Herpes Zoster Among Persons Living With HIV in the Current Antiretroviral Therapy Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 203-207.	0.9	65
51	Practice Patterns and Opinions in the Management of Recurrent or Chronic Herpes Zoster Ophthalmicus. <i>Cornea</i> , 2012, 31, 786-790.	0.9	37
52	The Shozu Herpes Zoster (SHEZ) Study: Rationale, Design, and Description of a Prospective Cohort Study. <i>Journal of Epidemiology</i> , 2012, 22, 167-174.	1.1	21
53	Zoster vaccine and biologic agents: time to question a paradigm?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 636-638.	3.5	0
54	Chronic Medical Conditions as Risk Factors for Herpes Zoster. <i>Mayo Clinic Proceedings</i> , 2012, 87, 961-967.	1.4	72
55	An Unusual Facial Ulcer. <i>Baylor University Medical Center Proceedings</i> , 2012, 25, 85-86.	0.2	0

#	ARTICLE	IF	CITATIONS
56	Where is reactivation after a long latency?. <i>BMJ Case Reports</i> , 2012, 2012, bcr0120125538-bcr0120125538.	0.2	6
57	A Pathway to Leadership for Adult Immunization: Recommendations of the National Vaccine Advisory Committee. <i>Public Health Reports</i> , 2012, 127, 1-42.	1.3	44
58	Novel Genetic Variation Identified at Fixed Loci in ORF62 of the Oka Varicella Vaccine and in a Case of Vaccine-Associated Herpes Zoster. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1533-1538.	1.8	31
59	Neuromuscular complications in HIV: effects of aging. <i>Journal of NeuroVirology</i> , 2012, 18, 331-338.	1.0	8
60	Epidemiology of Neuropathic Pain and Its Impact on Quality of Life. <i>Current Pain and Headache Reports</i> , 2012, 16, 191-198.	1.3	207
61	Association Between the Initiation of Anti-Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 887.	3.8	187
62	Varicella Zoster Virus in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 138-146.	2.6	63
63	Herpes Zoster. <i>New England Journal of Medicine</i> , 2013, 369, 255-263.	13.9	541
64	Assessment of vaccine candidates for persons aged 50 and older: a review. <i>BMC Geriatrics</i> , 2013, 13, 32.	1.1	22
65	An unexpected case of Ramsay hunt syndrome: case report and literature review. <i>BMC Research Notes</i> , 2013, 6, 337.	0.6	19
66	Vaccination Against and Treatment of Acute Herpes Zoster for Prevention of Post-Herpetic Neuralgia. <i>Current Pain and Headache Reports</i> , 2013, 17, 371.	1.3	2
67	Incidence of Herpes Zoster Ophthalmicus: Results from the Pacific Ocular Inflammation Study. <i>Ophthalmology</i> , 2013, 120, 451-456.	2.5	63
68	The case for Zostavax vaccination in systemic lupus erythematosus. <i>Vaccine</i> , 2013, 31, 3640-3643.	1.7	9
69	Improving Herpes Zoster Vaccination Rates Through Use of a Clinical Pharmacist and a Personal Health Record. <i>American Journal of Medicine</i> , 2013, 126, 832.e1-832.e6.	0.6	39
70	Self-report compared to electronic medical record across eight adult vaccines: Do results vary by demographic factors?. <i>Vaccine</i> , 2013, 31, 3928-3935.	1.7	202
71	Vaccination strategies in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 277-285.	8.2	24
72	Incidence and Time Trends of Herpes Zoster in Rheumatoid Arthritis: A Population-Based Cohort Study. <i>Arthritis Care and Research</i> , 2013, 65, 854-861.	1.5	80
73	Herpes Zoster Eye Complications: Rates and Trends. <i>Mayo Clinic Proceedings</i> , 2013, 88, 562-570.	1.4	130

#	ARTICLE	IF	CITATIONS
74	Clinical Outcomes and Management of Inflammatory Bowel Disease in the Older Patient. <i>Current Gastroenterology Reports</i> , 2013, 15, 310.	1.1	26
76	Prevention of infection caused by immunosuppressive drugs in gastroenterology. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 167-185.	1.1	72
77	Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster. <i>Journal of Infectious Diseases</i> , 2013, 208, 559-563.	1.9	36
78	Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study. <i>PLoS Medicine</i> , 2013, 10, e1001420.	3.9	183
79	Attenuation of the Adaptive Immune Response in Rhesus Macaques Infected with Simian Varicella Virus Lacking Open Reading Frame 61. <i>Journal of Virology</i> , 2013, 87, 2151-2163.	1.5	18
80	Varicella-Zoster Virus-Specific Antibody Responses in 50-59-Year-Old Recipients of Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2013, 208, 1386-1390.	1.9	41
81	Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity. <i>Journal of Rheumatology</i> , 2013, 40, 1875-1880.	1.0	53
82	Cutaneous Infections in Wrestlers. <i>Sports Health</i> , 2013, 5, 423-437.	1.3	19
83	Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su). <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1425-1429.	1.4	28
84	Effect of pharmacist intervention on herpes zoster vaccination in community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2013, 53, 46-53.	0.7	58
85	Examination of Links Between Herpes Zoster Incidence and Childhood Varicella Vaccination. <i>Annals of Internal Medicine</i> , 2013, 159, 739.	2.0	117
86	Herpes zoster vaccine in Korea. <i>Clinical and Experimental Vaccine Research</i> , 2013, 2, 92.	1.1	11
87	Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 3347.	1.4	28
88	Analgesia for pain during subcutaneous injection: effectiveness of manual pressure application before injection. <i>International Journal of General Medicine</i> , 2013, 6, 817.	0.8	5
89	Clinical use of anti-TNF therapy and increased risk of infections. <i>Drug, Healthcare and Patient Safety</i> , 2013, 5, 79.	1.0	185
90	Costs of moderate to severe chronic pain in primary care patients – a study of the ACCORD Program. <i>Journal of Pain Research</i> , 2014, 7, 389.	0.8	42
91	A guide to prepare patients with inflammatory bowel diseases for anti-TNF- α therapy. <i>Medical Science Monitor</i> , 2014, 20, 487-498.	0.5	31
92	Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1650-1660.	1.4	55

#	ARTICLE	IF	CITATIONS
93	Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009–2010): a GP-based prospective cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 637.	1.3	20
94	Relief of pain induced by varicella-zoster virus in a rat model of post-herpetic neuralgia using a herpes simplex virus vector expressing enkephalin. <i>Gene Therapy</i> , 2014, 21, 694-702.	2.3	24
95	Quantification of risk factors for herpes zoster: population based case-control study. <i>BMJ</i> , The, 2014, 348, g2911.	3.0	182
96	DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity. <i>Journal of Experimental Medicine</i> , 2014, 211, 2549-2566.	4.2	150
97	Bee Venom Treatment for Refractory Postherpetic Neuralgia: A Case Report. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, 212-214.	2.1	15
98	Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2675-2684.	2.9	290
99	Herpes zoster vaccine (HZV): utilization and coverage 2009 – 2013, Alberta, Canada. <i>BMC Public Health</i> , 2014, 14, 1098.	1.2	21
100	Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2014, 16, 506.	1.6	35
101	Improving Adherence to National Recommendations for Zoster Vaccination Through Simple Interventions. <i>Eye and Contact Lens</i> , 2014, 40, 225-231.	0.8	10
102	Herpes Zoster-Attributable Resource Utilization and Cost Burden in Patients With Solid Organ Transplant. <i>Transplantation</i> , 2014, 97, 1178-1184.	0.5	52
103	Viral Causes of Hearing Loss: A Review for Hearing Health Professionals. <i>Trends in Hearing</i> , 2014, 18, 233121651454136.	0.7	226
104	Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. <i>Rheumatology International</i> , 2014, 34, 151-163.	1.5	36
105	Health Maintenance and Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2014, 16, 402.	1.1	13
106	Immunization after kidney transplantation—what is necessary and what is safe?. <i>Nature Reviews Nephrology</i> , 2014, 10, 555-562.	4.1	18
107	Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997–2006. <i>Infection</i> , 2014, 42, 729-735.	2.3	52
109	Varicella-zoster. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 123, 265-283.	1.0	38
110	Vaccinations for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 431.	2.1	32
111	Association between recent herpes zoster but not herpes simplex infection and subsequent risk of malignancy in women: a retrospective cohort study. <i>Epidemiology and Infection</i> , 2014, 142, 1008-1017.	1.0	5

#	ARTICLE	IF	CITATIONS
112	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. <i>Blood</i> , 2014, 124, 2921-2929.	0.6	145
113	U.S. Physicians'™ Perspective of Adult Vaccine Delivery. <i>Annals of Internal Medicine</i> , 2014, 160, 161-170.	2.0	105
114	Survivorship: Immunizations and Prevention of Infections, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1098-1111.	2.3	16
115	Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. <i>Epidemiology and Infection</i> , 2015, 143, 2871-2881.	1.0	33
116	Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Community-based Prospective Cohort Study: The SHEZ Study. <i>Journal of Epidemiology</i> , 2015, 25, 617-625.	1.1	51
117	Varicella zoster virus infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15016.	18.1	435
118	Annual incidence rates of herpes zoster among an immunocompetent population in the United States. <i>BMC Infectious Diseases</i> , 2015, 15, 502.	1.3	99
119	Increasing Trends of Herpes Zoster in Australia. <i>PLoS ONE</i> , 2015, 10, e0125025.	1.1	40
120	Trends in Hospitalizations With Primary Varicella and Herpes Zoster During the Prevaricella and Initial Postvaricella and Herpes Zoster Vaccine Eras, Connecticut, 1994-2012. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv001.	0.4	12
121	Racial and Ethnic Disparities in Vaccination Coverage Among Adult Populations in the U.S.. <i>American Journal of Preventive Medicine</i> , 2015, 49, S412-S425.	1.6	113
122	Reducing the burden of Herpes Zoster in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 101-107.	1.4	13
123	Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2015, 212, 1222-1231.	1.9	24
124	Practical review of immunizations in adult patients with cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2606-2614.	1.4	42
125	Arsenic Exposure and Prevalence of the Varicella Zoster Virus in the United States: NHANES (2003-2004 and 2009-2010). <i>Environmental Health Perspectives</i> , 2015, 123, 590-596.	2.8	22
126	Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia. <i>Virology</i> , 2015, 482, 167-180.	1.1	28
127	Updates in vaccination: Recommendations for adult inflammatory bowel disease patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 3184-3196.	1.4	26
128	Headaches of the Elderly. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 30.	2.0	17
129	The epidemiology of herpes zoster and its complications in Medicare cancer patients. <i>BMC Infectious Diseases</i> , 2015, 15, 106.	1.3	37

#	ARTICLE	IF	CITATIONS
130	Varicella-Zoster Virus Infections in Patients Treated With Fingolimod. <i>JAMA Neurology</i> , 2015, 72, 31.	4.5	142
131	Screening and Vaccinations in Patients Requiring Systemic Immunosuppression: An Update for Dermatologists. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 179-195.	3.3	11
132	Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1157-1164.	1.4	39
133	Neuropathic Orofacial Pain. <i>Current Oral Health Reports</i> , 2015, 2, 148-157.	0.5	5
134	Herpes zoster and postherpetic neuralgia in Catalonia (Spain). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 178-184.	1.4	9
135	Postexposure management of healthcare personnel to infectious diseases. <i>Hospital Practice (1995)</i> , 2015, 43, 107-127.	0.5	2
136	Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. <i>Therapeutic Advances in Vaccines</i> , 2015, 3, 109-120.	2.7	155
137	Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013. <i>Journal of Primary Prevention</i> , 2015, 36, 259-273.	0.8	110
138	Zeroing in on zoster: A tale of many disorders produced by one virus. <i>Journal of the Neurological Sciences</i> , 2015, 358, 38-45.	0.3	19
139	Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 1279-1287.	1.9	172
140	Altered homotopic connectivity in postherpetic neuralgia: a resting state fMRI study. <i>Journal of Pain Research</i> , 2016, Volume 9, 877-886.	0.8	29
141	A Study of Intravenous Administration of Vitamin C in the Treatment of Acute Herpetic Pain and Postherpetic Neuralgia. <i>Annals of Dermatology</i> , 2016, 28, 677.	0.3	42
142	Evaluation of the acceptability of a vaccine against herpes zoster in the over 50 years old: an Italian observational study. <i>BMJ Open</i> , 2016, 6, e011539.	0.8	24
143	Initial Presentation Sites as Predictors of Herpes Zoster Complications: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0164019.	1.1	6
144	Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. <i>Journal of Multidisciplinary Healthcare</i> , 2016, Volume 9, 447-454.	1.1	128
145	Risk Factors for Herpes Zoster Among Adults. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw119.	0.4	42
146	Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. <i>Arthritis and Rheumatology</i> , 2016, 68, 2328-2337.	2.9	150
147	Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 1561-1569.	0.7	86

#	ARTICLE	IF	CITATIONS
148	Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2205-2216.	1.1	9
149	Epidemiology of Herpes Zoster Ophthalmicus. <i>Ophthalmology</i> , 2016, 123, 1469-1475.	2.5	80
150	A Multifaceted Intervention to Improve Influenza, Pneumococcal, and Herpes Zoster Vaccination among Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1030-1037.	1.0	25
151	Efficacy of varicella (VZV) vaccination: an update for the clinician. <i>Therapeutic Advances in Vaccines</i> , 2016, 4, 20-31.	2.7	32
152	Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw205.	0.4	81
153	Impact of Underlying Conditions on Zoster-Related Pain and on Quality of Life Following Zoster. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw189.	1.7	11
154	Health Services for Management of Chronic Non-Cancer Pain in Kuwait: A Case Study Review. <i>Medical Principles and Practice</i> , 2016, 25, 29-42.	1.1	4
155	Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 221-226.	2.9	135
156	Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review. <i>Advances in Therapy</i> , 2016, 33, 1094-1104.	1.3	22
157	Self-reported herpes zoster, pain, and health care seeking in the Health and Retirement Study: implications for interpretation of health care-based studies. <i>Annals of Epidemiology</i> , 2016, 26, 441-446.e3.	0.9	20
158	Risk of Stroke and Myocardial Infarction After Herpes Zoster in Older Adults in a US Community Population. <i>Mayo Clinic Proceedings</i> , 2016, 91, 33-44.	1.4	57
159	Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2092-2095.	1.4	21
160	Primary care physicians' perspective on financial issues and adult immunization in the Era of the Affordable Care Act. <i>Vaccine</i> , 2017, 35, 647-654.	1.7	35
161	ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 241-258.	0.2	364
162	The emerging safety profile of JAK inhibitors in rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2017, 13, 234-243.	3.5	420
163	Ramsay Hunt syndrome. <i>Cmaj</i> , 2017, 189, E320-E320.	0.9	2
164	Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature review. <i>Expert Review of Vaccines</i> , 2017, 16, 391-400.	2.0	37
165	Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. <i>BMC Infectious Diseases</i> , 2017, 17, 213.	1.3	58

#	ARTICLE	IF	CITATIONS
166	Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015. <i>Vaccine</i> , 2017, 35, 3104-3115.	1.7	38
167	Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis. <i>Annals of Hematology</i> , 2017, 96, 311-315.	0.8	10
168	Trends in Nationwide Herpes Zoster Emergency Department Utilization From 2006 to 2013. <i>JAMA Dermatology</i> , 2017, 153, 874.	2.0	10
169	Lateral thalamic control of nociceptive response after whisker pad injection of varicella zoster virus. <i>Neuroscience</i> , 2017, 356, 207-216.	1.1	14
170	Temporal trends in herpes zoster-related hospitalizations in Italy, 2001–2013: differences between regions that have or have not implemented varicella vaccination. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 771-779.	1.4	11
171	Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. <i>Journal of Rheumatology</i> , 2017, 44, 1083-1087.	1.0	27
172	Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 505-511.	2.0	35
173	Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 391-398.	1.4	17
174	Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 574-578.	1.4	18
175	Varicella and herpes zoster vaccine development: lessons learned. <i>Expert Review of Vaccines</i> , 2017, 16, 1191-1201.	2.0	49
176	Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older. <i>Journal of Infectious Diseases</i> , 2017, 216, 1352-1361.	1.9	63
177	The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1969-1977.	2.9	103
178	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. <i>Arthritis and Rheumatology</i> , 2017, 69, 1960-1968.	2.9	182
179	Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 607-619.	0.8	8
180	Identifying heavy health care users among primary care patients with chronic non-cancer pain. <i>Canadian Journal of Pain</i> , 2017, 1, 22-36.	0.6	5
181	Sex differences underlying orofacial varicella zoster associated pain in rats. <i>BMC Neurology</i> , 2017, 17, 95.	0.8	20
182	The temporal impact of aging on the burden of herpes zoster. <i>BMC Geriatrics</i> , 2017, 17, 30.	1.1	54
183	Guidelines for the prevention of travel-associated illness in older adults. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2017, 3, 10.	0.9	21

#	ARTICLE	IF	CITATIONS
184	National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years. <i>American Journal of Preventive Medicine</i> , 2017, 52, 362-372.	1.6	29
185	Herpes Zoster Vaccine: Time for a Boost?. <i>Journal of General Internal Medicine</i> , 2017, 32, 145-147.	1.3	2
186	Herpes zoster and the search for an effective vaccine. <i>Clinical and Experimental Immunology</i> , 2016, 187, 82-92.	1.1	19
187	Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2017, 69, 439-446.	2.9	24
188	Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2017, 216, 1343-1351.	1.9	45
189	Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine. <i>Journal of Infectious Diseases</i> , 2017, 216, 1329-1333.	1.9	4
190	Impact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization. <i>BMC Health Services Research</i> , 2017, 17, 503.	0.9	5
191	Herpes Zoster and Recurrent Herpes Zoster. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx007.	0.4	49
192	Acute urinary retention and constipation precipitated by herpes zoster infection. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220068.	0.2	4
193	Disseminated herpes zoster causing acute respiratory distress syndrome in an immunocompetent patient. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220542.	0.2	4
194	Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis. <i>Frontiers in Immunology</i> , 2017, 8, 1377.	2.2	8
195	Role for the Ventral Posterior Medial/Posterior Lateral Thalamus and Anterior Cingulate Cortex in Affective/Motivation Pain Induced by Varicella Zoster Virus. <i>Frontiers in Integrative Neuroscience</i> , 2017, 11, 27.	1.0	11
196	Healthcare maintenance in elderly patients with inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2017, 30, 273-286.	0.4	8
197	Surveillance of Vaccination Coverage among Adult Populations – United States, 2015. <i>MMWR Surveillance Summaries</i> , 2017, 66, 1-28.	18.6	327
198	Herpes Zoster and Diabetes Mellitus: A Review. <i>Diabetes Therapy</i> , 2018, 9, 545-550.	1.2	47
199	Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. <i>JAMA Internal Medicine</i> , 2018, 178, 248.	2.6	52
200	Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list. <i>Pediatric Rheumatology</i> , 2018, 16, 15.	0.9	28
201	Vaccines for the elderly: current use and future challenges. <i>Immunity and Ageing</i> , 2018, 15, 3.	1.8	127

#	ARTICLE	IF	CITATIONS
202	Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006–2015. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1963-1969.	1.4	24
203	Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 217, 1055-1059.	1.9	8
204	Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. <i>American Journal of Epidemiology</i> , 2018, 187, 161-169.	1.6	70
205	In vivo confocal microscopy detects bilateral changes of corneal immune cells and nerves in unilateral herpes zoster ophthalmicus. <i>Ocular Surface</i> , 2018, 16, 101-111.	2.2	79
206	Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 103-108.	9.0	420
207	Impact of Out-of-Pocket Cost on Herpes Zoster Vaccine Uptake: An Observational Study in a Medicare Managed Care Population. <i>Vaccines</i> , 2018, 6, 78.	2.1	2
208	Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons. <i>AIDS Research and Therapy</i> , 2018, 15, 25.	0.7	2
209	Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 527-533.	0.9	7
210	Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity. <i>Immune Network</i> , 2018, 18, e38.	1.6	9
211	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. <i>Haematologica</i> , 2018, 103, e492-e495.	1.7	6
212	Update on Vaccinating the Patient With Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 548-560.	0.3	5
213	A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1401-1411.	1.1	9
214	The effect of ultrasound-guided percutaneous ozone injection around cervical dorsal root ganglion in zoster-associated pain: a retrospective study. <i>Journal of Pain Research</i> , 2018, Volume 11, 2179-2188.	0.8	10
215	Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus. <i>Journal of Korean Medical Science</i> , 2018, 33, e252.	1.1	6
216	Primary care physicians'™ experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). <i>Vaccine</i> , 2018, 36, 7408-7414.	1.7	18
217	Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus. <i>Frontiers in Integrative Neuroscience</i> , 2018, 12, 46.	1.0	22
218	The Economic Impact of Herpes Zoster Vaccine Disparities in Elderly United States Blacks. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2128.	1.2	2
219	A cross-sectional survey of work and income loss consideration among patients with herpes zoster when completing a quality of life questionnaire. <i>BMC Health Services Research</i> , 2018, 18, 662.	0.9	4

#	ARTICLE	IF	CITATIONS
220	Modalities in managing postherpetic neuralgia. <i>Korean Journal of Pain</i> , 2018, 31, 235-243.	0.8	50
221	Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2173-2182.	0.9	83
222	Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2258-2265.	0.9	175
223	A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-4.	1.4	16
224	Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy. <i>Frontiers in Public Health</i> , 2018, 6, 70.	1.3	8
225	Successful Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2018, 428, 1-30.	0.7	22
226	Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review. <i>BMC Rheumatology</i> , 2018, 2, 2.	0.6	20
227	Risk and impact of herpes zoster among COPD patients: a population-based study, 2009–2014. <i>BMC Infectious Diseases</i> , 2018, 18, 203.	1.3	23
228	Recommendations and barriers to vaccination in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2018, 17, 990-1001.	2.5	24
229	Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature. <i>Frontiers in Immunology</i> , 2018, 9, 1632.	2.2	24
230	Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012. <i>BMJ Open</i> , 2018, 8, e020528.	0.8	55
231	Cross-sectional study on hospitalizations related to herpes zoster in an Italian region, 2008–2016. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 145-150.	1.4	8
232	Herpes zoster vaccination in systemic lupus erythematosus: the current status. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 45-48.	1.4	20
233	Infectious Disease in Contact Sports. <i>Sports Health</i> , 2019, 11, 47-58.	1.3	37
234	Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 625.	1.3	14
235	Insurance Reimbursements for Routinely Recommended Adult Vaccines in the Private Sector. <i>American Journal of Preventive Medicine</i> , 2019, 57, 180-190.	1.6	11
236	A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz219.	0.4	11
237	A Case of Varicella-Zoster Meningoencephalitis Presented by Ramsay Hunt Syndrome. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2019, 71, 1508-1510.	0.3	1

#	ARTICLE	IF	CITATIONS
238	Insights into the Pathogenesis of Varicella Viruses. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 156-165.	1.8	6
239	Estradiol Acts in Lateral Thalamic Region to Attenuate Varicella Zoster Virus Associated Affective Pain. <i>Neuroscience</i> , 2019, 414, 99-111.	1.1	21
240	A Community-Based Survey to Assess Knowledge, Attitudes, Beliefs and Practices Regarding Herpes Zoster in an Urban Setting. <i>Infectious Diseases and Therapy</i> , 2019, 8, 687-694.	1.8	14
241	A case of tri-segmental cranial nerve V herpes zoster. <i>IDCases</i> , 2019, 18, e00642.	0.4	1
242	Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 70, 1509-1515.	2.9	12
243	Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60+. <i>Journal of Pharmacy Technology</i> , 2019, 35, 258-269.	0.5	1
244	Recurrent herpes zoster ophthalmicus in a young, healthy individual taking high doses of L-Arginine. <i>American Journal of Ophthalmology Case Reports</i> , 2019, 16, 100547.	0.4	6
245	<p>Varicella zoster virus vaccines: an update</p>. <i>ImmunoTargets and Therapy</i> , 2019, Volume 8, 15-28.	2.7	29
246	Short-term efficacy and safety of prednisone in herpes zoster and the effects on IL-6 and IL-10. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 2893-2900.	0.8	4
247	Low level of hemoglobin A1c and the increased incidence of herpes zoster: longitudinal study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1539-1545.	1.3	5
248	Patient report of herpes zoster pain: Incremental benefits of zoster vaccine live. <i>Vaccine</i> , 2019, 37, 3478-3484.	1.7	10
249	Improving immunization strategies in patients with inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2019, 32, 247-256.	0.4	13
250	Vaccination differences among U.S. adults by their self-identified sexual orientation, National Health Interview Survey, 2013-2015. <i>PLoS ONE</i> , 2019, 14, e0213431.	1.1	20
251	Post-total knee arthroplasty herpes zoster activation. <i>BMJ Case Reports</i> , 2019, 12, e228639.	0.2	3
252	Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2019. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 115-118.	9.0	35
253	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. <i>Cancer</i> , 2019, 125, 1301-1312.	2.0	68
254	Adult vaccination as the cornerstone of successful ageing: the case of herpes zoster vaccination. A European Interdisciplinary Council on Ageing (EICA) expert focus group. <i>Ageing Clinical and Experimental Research</i> , 2019, 31, 301-307.	1.4	4
255	Varicella Zoster Virus Encephalitis. <i>Clinical Practice and Cases in Emergency Medicine</i> , 2019, 3, 380-382.	0.1	20

#	ARTICLE	IF	CITATIONS
256	Herpes zoster increased risk of neuralgic amyotrophy: a retrospective, population-based matched cohort study. <i>Journal of NeuroVirology</i> , 2019, 25, 91-100.	1.0	2
257	Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 765-771.	1.4	15
258	Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. <i>Pharmacoeconomics</i> , 2019, 37, 169-200.	1.7	24
259	Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. <i>Arthritis Care and Research</i> , 2020, 72, 353-359.	1.5	23
260	Horner's Syndrome Following Varicella Vaccination. <i>Neuro-Ophthalmology</i> , 2020, 44, 267-269.	0.4	5
261	Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 219-227.	1.3	17
262	Incidence Rate of Herpes Zoster Ophthalmicus. <i>Ophthalmology</i> , 2020, 127, 324-330.	2.5	39
263	The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence. <i>Journal of Infectious Diseases</i> , 2020, 222, 798-806.	1.9	61
264	Ixekizumab and herpes zoster in an erythrodermic patient. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 417-418.	0.2	0
265	JAK inhibitors and infections risk: focus on herpes zoster. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093605.	1.2	72
266	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 914-929.	0.6	29
267	A global agenda for older adult immunization in the COVID-19 era: A roadmap for action. <i>Vaccine</i> , 2021, 39, 5240-5250.	1.7	52
268	Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa274.	0.4	8
269	Herpes Zoster and Postherpetic Neuralgia: Changing Incidence Rates From 1994 to 2018 in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e3210-e3217.	2.9	51
270	Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa172.	0.4	6
271	Herpes zoster of the trigeminal nerve with multi-dermatomal involvement: a case report of an unusual presentation. <i>BMC Dermatology</i> , 2020, 20, 12.	2.1	7
272	Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. <i>ACR Open Rheumatology</i> , 2020, 2, 357-361.	0.9	43
273	Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine. <i>American Journal of Preventive Medicine</i> , 2020, 59, 21-31.	1.6	11

#	ARTICLE	IF	CITATIONS
274	Effect of herpes zoster vaccine and antiviral treatment on risk of ischemic stroke. <i>Neurology</i> , 2020, 95, e708-e717.	1.5	13
275	Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 513-532.	1.1	4
276	The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2021, 224, 1139-1146.	1.9	12
277	The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients ≥50 Years. <i>Vaccines</i> , 2020, 8, 20.	2.1	8
278	Association of herpes zoster and chronic inflammatory skin disease in US inpatients. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1437-1445.	0.6	12
279	Vaccination in Patients with Inflammatory Bowel Diseases. <i>Digestion</i> , 2020, 101, 58-68.	1.2	29
280	Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data. <i>BMJ</i> , 2020, 368, l6987.	3.0	22
281	Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 278-284.	0.6	5
282	Outpatient healthcare utilization and prescribing patterns for herpes zoster in United States adults. <i>Archives of Dermatological Research</i> , 2021, 313, 155-162.	1.1	4
283	The role of social determinants in timely herpes zoster vaccination among older American adults. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2043-2049.	1.4	11
284	Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 949-956.	2.9	34
285	A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. <i>Clinical Rheumatology</i> , 2021, 40, 3533-3545.	1.0	31
286	A systematic literature review of herpes zoster incidence worldwide. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1714-1732.	1.4	66
287	Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States. <i>Ophthalmology</i> , 2021, 128, 1699-1707.	2.5	18
288	Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries. <i>Stroke</i> , 2021, 52, 1712-1721.	1.0	16
289	Osteopathic Manipulative Treatment of Herpes Zoster Ophthalmicus/Postherpetic Neuralgia. <i>Cureus</i> , 2021, 13, e14906.	0.2	0
290	Risk of Herpes Zoster Among Psoriasis Patients Taking Biologics: A Network Meta-Analysis of Cohort Studies. <i>Frontiers in Medicine</i> , 2021, 8, 665559.	1.2	7
291	Estimated Public Health Impact of the Recombinant Zoster Vaccine. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 596-604.	1.2	3

#	ARTICLE	IF	CITATIONS
292	Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3735-3746.	1.4	10
293	Insurance reimbursements for recombinant zoster vaccine in the private sector. <i>Vaccine</i> , 2021, 39, 5091-5094.	1.7	3
294	Sterile iris abscess associated with herpes zoster ophthalmicus. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 23, 101144.	0.4	1
295	Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients. <i>BMC Infectious Diseases</i> , 2021, 21, 117.	1.3	7
296	Herpes zoster (shingles) and postherpetic neuralgia. <i>Mayo Clinic Proceedings</i> , 2009, 84, 274-80.	1.4	100
297	Revisiting the genotyping scheme for varicella-zoster viruses based on whole-genome comparisons. <i>Journal of General Virology</i> , 2017, 98, 1434-1438.	1.3	28
298	Severe perianal shingles during azathioprine and budesonide treatment for Crohn's disease—preventable with zoster vaccine?. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216527.	0.2	4
299	Varicella-zoster virus reactivation during acute enterovirus infection is associated with CD8 lymphocytopenia. <i>BMJ Case Reports</i> , 2009, 2009, bcr0820080803-bcr0820080803.	0.2	2
300	Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014. <i>BMC Infectious Diseases</i> , 2020, 20, 905.	1.3	24
301	Disease Burden Due to Herpes Zoster among Population Aged ≥50 Years Old in China: A Community Based Retrospective Survey. <i>PLoS ONE</i> , 2016, 11, e0152660.	1.1	26
302	STATEMENT ON THE RECOMMENDED USE OF HERPES ZOSTER VACCINE. <i>Canada Communicable Disease Report</i> , 2010, 36, 1-19.	0.6	4
303	Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2018. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 158-160.	9.0	38
304	Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine – United States, 2017–2018. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 585-586.	9.0	11
305	Monitoring Interest in Herpes Zoster Vaccination: Analysis of Google Search Data. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e10180.	1.2	21
306	Zoster sine herpette: a review. <i>Korean Journal of Pain</i> , 2020, 33, 208-215.	0.8	36
307	Vaccines and recommendations for their use in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 1354.	1.4	16
308	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11273.	1.4	46
309	A prospective study of herpes zoster in children. <i>Indian Journal of Dermatology</i> , 2016, 61, 534.	0.1	17

#	ARTICLE	IF	CITATIONS
310	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 387.	0.6	6
311	Toll-like Receptors in Viral Encephalitis. Viruses, 2021, 13, 2065.	1.5	10
312	Childhood Immunization Policies and the Prevention of Communicable Disease. Pediatric Annals, 2011, 40, 136-143.	0.3	0
313	Ramsay Hunt syndrome in a patient with human immunodeficiency virus infection. Indian Journal of Sexually Transmitted Diseases and AIDS, 2017, 38, 89.	0.6	1
314	Clinical Efficacy of Pretransplant Vaccination for Preventing Herpes Zoster After Living Donor Liver Transplantation in Recipients Age 50 Years and Older. Annals of Transplantation, 2019, 24, 208-213.	0.5	2
315	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. American Journal of Hematology, 2022, 97, 90-98.	2.0	13
316	Recurrent Herpes Zoster Ophthalmicus Preceded by Anabolic Steroids and High-Dose L-Arginine. Case Reports in Ophthalmological Medicine, 2020, 2020, 1-4.	0.3	3
317	Generalized Rash and Bilateral Retinal Necrosis in an Adult Healthcare Worker after Post-Exposure Herpes Zoster Vaccination: A Rare Case Report. Kansas Journal of Medicine, 2020, 13, 324-325.	0.1	0
319	Wet cupping therapy for treatment of herpes zoster: a systematic review of randomized controlled trials. Alternative Therapies in Health and Medicine, 2010, 16, 48-54.	0.0	23
320	Update on herpes zoster vaccination: a family practitioner's guide. Canadian Family Physician, 2011, 57, 1127-31.	0.1	20
321	Cutaneous infections and infestations: new therapies. Journal of Clinical and Aesthetic Dermatology, 2011, 4, 18-24.	0.1	40
322	Immune aging and challenges for immune protection of the graying population. , 2011, 2, 339-45.		3
323	Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. Gastroenterology and Hepatology, 2012, 8, 504-12.	0.2	10
324	Zoster vaccine. Canadian Family Physician, 2013, 59, 157.	0.1	1
325	Disseminated Varicella Zoster Virus Infection with Encephalitis in a UC Patient Receiving Infliximab. Gastroenterology and Hepatology, 2013, 9, 54-6.	0.2	4
326	Things are not as bad as they seem: physicians' ability to predict their clinical practice when a new vaccine becomes available. Healthcare Policy, 2013, 8, 71-85.	0.3	3
327	Environmental influences on the onset and clinical course of Crohn's disease-part 2: infections and medication use. Gastroenterology and Hepatology, 2013, 9, 803-10.	0.2	4
328	Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterology and Hepatology, 2014, 10, 355-63.	0.2	10

#	ARTICLE	IF	CITATIONS
330	Evaluation of efficacy and effectiveness of live attenuated zoster vaccine. <i>Journal of Preventive Medicine and Hygiene</i> , 2014, 55, 130-6.	0.9	7
331	Adult immunization schedule. The general practitioner's perspective and new tools for a better practice. <i>Journal of Preventive Medicine and Hygiene</i> , 2015, 56, E9-E11.	0.9	0
332	Eye and Periocular Skin Involvement in Herpes Zoster Infection. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2015, 4, 142-156.	0.4	7
333	Vaccinating Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2016, 12, 540-546.	0.2	18
335	Vaccination and Health Maintenance Issues to Consider in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017, 13, 717-724.	0.2	3
336	Update on recommendations for use of herpes zoster vaccine. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 729-31.	9.0	113
337	Closure of varicella-zoster virus-containing vaccines pregnancy registry - United States, 2013. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 732-3.	9.0	16
339	Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance. , 2021, 9, 251513552110574.	1.4	5
340	Change in Cav3.2 T-Type Calcium Channel Induced by Varicella-Zoster Virus Participates in the Maintenance of Herpetic Neuralgia. <i>Frontiers in Neurology</i> , 2021, 12, 741054.	1.1	8
341	Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010â€“2018. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5304-5310.	1.4	5
342	A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patientsâ€™ Health-Related Quality of Life. <i>Infectious Diseases and Therapy</i> , 2022, 11, 501.	1.8	6
343	Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged â‰¥19 Years: Recommendations of the Advisory Committee on Immunization Practices â€” United States, 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 80-84.	9.0	91
344	Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac011.	0.4	3
345	Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report. <i>IDCases</i> , 2022, 27, e01452.	0.4	3
346	Herpes Zoster Ophthalmicus: A Devastating Disease Coming Back with Vengeance or Finding Its Nemesis?. <i>Journal of Ophthalmic and Vision Research</i> , 2022, 17, 123-129.	0.7	1
347	Vaccine Strain and Wild-Type Clades of Varicella-Zoster Virus in Central Nervous System and Non-CNS Disease, New York State, 2004â€“2019. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0238121.	1.8	2
348	Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles. <i>Viruses</i> , 2022, 14, 588.	1.5	6
349	Acupuncture therapies for postherpetic neuralgia: a protocol for a systematic review and Bayesian network meta-analysis. <i>BMJ Open</i> , 2022, 12, e056632.	0.8	5

#	ARTICLE	IF	CITATIONS
350	Knowledge and Attitudes Concerning Herpes Zoster among People with COPD: An Interventional Survey Study. <i>Vaccines</i> , 2022, 10, 420.	2.1	7
351	Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	3
352	Meta-Regression of Herpes Zoster Incidence Worldwide. <i>Infectious Diseases and Therapy</i> , 2022, 11, 389-403.	1.8	20
353	Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application. <i>Pharmaceutics</i> , 2021, 13, 2091.	2.0	19
354	Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. <i>Rheumatology and Therapy</i> , 2022, 9, 243-263.	1.1	7